Opinion|Videos|March 1, 2024
Recent Subgroup Analyses from the CLEAR study in Advanced RCC
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.
Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5